COCP: Cocrystal Pharma, Inc. Cash on Hand per Share

Cash per share demonstrates current liquidity, where the parameter value reaches 0.26. Cocrystal Pharma, Inc. (COCP) utilizes protein crystallography to create structural barriers against viral replication. The issuer's revenues will be based on the market launch of therapies against COVID-19, influenza, and norovirus. Operating within the US jurisdiction minimizes geopolitical risks, ensuring legal protection for the business.
Analytical breakdowns for Cocrystal Pharma, Inc.

Cash per share measures the portion of liquid assets attributable to a single security, determining the issuer's financial autonomy. For Cocrystal Pharma, Inc. (COCP), this resource is critical as it ensures the independence of academic R&D centers and the payment of options to leading virologists. By analyzing the cash per share chart, one can assess the capital burn rate. A rising trend confirms stability, while a sharp decline signals the risk of external borrowing.